Vaccines

Ogilvie RP, Layton JB, Lloyd PC, Jiao Y, Djibo DA, Wong HL, Gruber JF, Parambi R, Deng J, Miller M, Song J, Weatherby LB, Peetluk L, Lo A, Matuska K, Wernecke M, Bui CL, Clarke TC, Cho S, Bell EJ, Yang G, Amend KL, Forshee RA, Anderson SA, McMahill-Walraven CN, Chillarige Y, Anthony MS, Seeger JD, Shoaibi A. Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study. BMC Pediatr. 2024 Apr 26;24(1):276. doi: 10.1186/s12887-024-04756-5


BACKGROUND: COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. This study’s objective was to estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children.

Samant S, Oberle S, Marcek T, Poulos C, Chintakayala PK, Langevin E, Petigara T, Boeri M. Preferences of healthcare providers in Switzerland for attributes of pediatric hexavalent vaccines. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S318-9. doi: 10.1016/j.jval.2023.09.1679


OBJECTIVES: To understand the preferences of Swiss healthcare providers (HCPs) for attributes of pediatric hexavalent vaccines.

Boeri M, Marcek T, Chintakayala PK, Poulos C, Francis A, Langevin E, Balogh O, Petigara T, O’Connor J, Samant S. Preferences of nurses for attributes of pediatric hexavalent vaccines in the United Kingdom. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S313. doi: 10.1016/j.jval.2023.09.1653


OBJECTIVES: To understand the preferences of UK nurses for attributes of pediatric hexavalent vaccines.

Wilson M, Lucas A, Mendes D, Vyse A, Mikudina B, Czudek C, Ellsbury GF, Perdrizet J. Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom. Vaccines (Basel). 2023 Jun 28;11(7):1168. doi: 10.3390/vaccines11071168


Cook C, Carrico J, Talbird S, Sabale U, Dolk C, Bencina G. Public health impact of the pediatric immunization program in the Netherlands. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S135-6. doi: 10.1016/j.jval.2023.09.705


OBJECTIVES: To assess the public health impact of the pediatric immunization program (PIP) in the Netherlands.

Mellott CE, Jaworski R, Carrico J, Talbird SE, Dobrowolska I, Golicki D, Bencina G, Clinkscales M, Karamousouli E, Eiden AL, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland. Expert Rev Vaccines. 2023 Dec;22(11):1114-25. doi: 10.1080/14760584.2023.2275712


BACKGROUND: This study aimed to evaluate the epidemiological impact and return on investment of the pediatric immunization program (PIP) in Poland from the healthcare-sector and societal perspectives.

Barbieri M, Senese F, Mellott CE, Boccalini S, Carrico J, Bechini A, Talbird SE, Chen Y-H, Bencina G. Public health impact and return on investment of the pediatric national immunization program in Italy. Presented at the Italian Society of Hygiene, Preventive Medicine, and Public Health Conference; October 12, 2023. Cernobbio, Italy.


OBJECTIVES: To evaluate the economic impact of the pediatric National Immunization Program (NIP) in Italy from both healthcare sector and societal perspectives.

Shamarina D, Sluga-O'Callaghan M, Dave V, Davenport E, Curran D, Deeywadaa P, Marijam A, Andani A. Knowledge and attitudes of European HCPs towards hepatitis A and B vaccination of adults at risk. Poster presented at the Global Hepatitis Summit 2023; April 25, 2023. Paris, France. Previously presented at the 15th European Public Health Conference 2022 (EPH).


Carrico J, Mellott CE, Talbird SE, Bento-Abreu A, Merckx B, Vandenhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Eiden A, Nyaku MK, Bencina G. Public health impact and return on investment of Belgium's pediatric immunization program. Front Public Health. 2023 Jun 22;11:1032385. doi: 10.3389/fpubh.2023.1032385


OBJECTIVE: We evaluated the public health impact and return on investment of Belgium’s pediatric immunization program (PIP) from both healthcare-sector and societal perspectives.

Ahmadizar F, Fortuny J, Cid-Royo A, Plana E, Weinrib R, Garcia Esteban R, Boric K, Yefimenko N, Carreras JJ, Urcheguia A, Correcher-Martinez E, Mira-Iglesias A, Swart KMA, van den Berg JM, Overbeek JA, Villalonos F, Bissacco CA, Newbern C, Praet N, Willame C, Sturkenboom M. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data: methods and results of the first study feasibility assessment. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):189-90. doi: 10.1002/pds.5687


BACKGROUND: As part of the lifecycle benefit-risk assessment of vaccines, a post-authorisation safety study (PASS) using real-world data was required by EMA-PRAC to characterise and evaluate the safety of the JCOVDEN.

Subscribe to Vaccines

How Can We Help You?